Genor Biopharma Holdings Limited (6998.HK)

1.250 -0.030 (-2.34%) At close: 04:08PM HKT

Genor Biopharma Holdings Limited

Building 3
1690 Zhangheng Road Pudong New District
Shanghai 201203
China
86 21 6169 0700
https://www.genorbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 104

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Feng Guo Ph.D.	CEO & Chairman	7.95M	N/A	1970
Mr. Chengyi Weng	Vice President of Finance	N/A	N/A	N/A
Mr. Qibin Liang	Chief Technology Officer	N/A	N/A	1957
Dr. Shuhua Han Ph.D.	Chief Scientist	N/A	N/A	1959
Ms. Xiaojing Zhu	Vice President of Compliance & Administration	N/A	N/A	N/A
Mr. Tong Li M.D.	Chief Medical Officer	N/A	N/A	1969
Mr. Tak Wai Ip	Company Secretary	N/A	N/A	N/A
Mr. Jun Lin	Vice President of Quality Analysis	N/A	N/A	1985
Mr. Qingtang Duan	General Manager of Yuxi Genor	N/A	N/A	1983

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB267, and GB266 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Corporate governance

Genor Biopharma Holdings Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.